Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2014 | Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma

Jeffrey Matous • 6 Dec 2014
ASH 2014
Multiple Myeloma Carfilzomib Dexamethasone Lenalidomide

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffrey Matous (Colorado Blood Cancer Institute, Denver, CO) discusses the randomised, open-label, multicentre phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma.

More from Jeffrey Matous

The growing importance of bispecific antibodies in the treatment of multiple myeloma 1:47
The growing importance of bispecific antibodies in the treatment of multiple myeloma
Jeffrey Matous • 9 Dec 2024
Investigating higher teclistamab step-up dosing in R/R myeloma: results from MajesTEC-1 3:41
Investigating higher teclistamab step-up dosing in R/R myeloma: results from MajesTEC-1
Jeffrey Matous • 9 Dec 2024
An ongoing clinical trial investigating sonrotoclax in Waldenström’s macroglobulinemia 1:19
An ongoing clinical trial investigating sonrotoclax in Waldenström’s macroglobulinemia
Jeffrey Matous • 19 Oct 2024
A trial by WM-NET investigating bendamustine, rituximab, and fixed-duration zanubrutinib in WM 1:04
A trial by WM-NET investigating bendamustine, rituximab, and fixed-duration zanubrutinib in WM
Jeffrey Matous • 19 Oct 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals